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The Efficacy of Epidermal Growth Factor Receptor^Specific
Antibodies against Glioma Xenografts Is Influenced by
Receptor Levels,ActivationStatus, andHeterodimerization
Terrance G. Johns,1RushikaM. Perera,1Sonja C.Vernes,1Angela A.Vitali,1Diana X. Cao,1
Webster K. Cavenee,3 AndrewM. Scott,2 and Frank B. Furnari3
Abstract Purpose: Factors affecting the efficacy of therapeutic monoclonal antibodies (mAb) directed to
the epidermal growth factor receptor (EGFR) remain relatively unknown, especially in glioma.
Experimental Design:We examined the efficacy of two EGFR-specific mAbs (mAbs 806 and
528) against U87MG-derived glioma xenografts expressing EGFR variants. Using this approach
allowed us to change the form of the EGFR while keeping the genetic background constant.
These variants included the de2-7 EGFR (or EGFRvIII), a constitutively active mutation of the
EGFR expressed in glioma.
Results:The efficacy of the mAbs correlated with EGFR number; however, the most important
factor was receptor activation. Whereas U87MG xenografts expressing the de2-7 EGFR
responded to therapy, those exhibiting a dead kinase de2-7 EGFR were refractory. A modified
de2-7 EGFR that was kinase active but autophosphorylationdeficient also responded, suggesting
that these mAbs function in de2-7 EGFR ^ expressing xenografts by blocking transphosphoryla-
tion. Because de2-7 EGFR ^ expressing U87MG xenografts coexpress the wild-type EGFR,
efficacy of the mAbs was also tested against NR6 xenografts that expressed the de2-7 EGFR in
isolation.Whereas mAb 806 displayed antitumor activity against NR6 xenografts, mAb 528
therapy was ineffective, suggesting that mAb 528 mediates its antitumor activity by disrupting
interactions between the de2-7 and wild-type EGFR. Finally, genetic disruption of Src in
U87MG xenografts expressing the de2-7 EGFR dramatically enhanced mAb 806 efficacy.
Conclusions:The effective use of EGFR-specific antibodies in gliomawill depend on identifying
tumors with activated EGFR. The combination of EGFR and Src inhibitors may be an effective
strategy for the treatment of glioma.
The epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein with intrinsic tyrosine kinase activity.
Overexpression of the EGFR is observed in numerous epithelial
tumors and is often associated with a poorer clinical prognosis
(1–3). Overexpression of the EGFR can result from EGFR
gene amplification, particularly in glioma (4). In glioma, gene
amplification is associated with EGFR rearrangements with
the most common mutation, the de2-7 EGFR (or EGFRvIII),
characterized by an in-frame deletion of 801 bp spanning exons
2 to 7 of the coding sequence (4–6). This rearrangement results
in the deletion of 267 amino acids from the extracellular
domain and the insertion of a novel glycine at the fusion site, all
of which produces a unique junctional peptide. Although the
de2-7 EGFR is unable to bind any known ligand, the receptor
displays a low level of constitutive activation and is able to
enhance the growth of glioma and breast cancer xenografts (7, 8).
Inhibition of the EGFR is a rational strategy for the deve-
lopment of new cancer therapeutics. Potential therapeutics
include monoclonal antibodies (mAb) directed to the EGFR
(e.g., C225, ABX-EGF, and EMD55900; refs. 9–11) and small
molecular weight tyrosine kinase inhibitors (TKI) of the EGFR
(e.g., ZD1839 and OSI-774; ref. 12). Indeed, some of these
therapeutics have been approved for limited clinical use in
lung cancer (ZD1839, Iressa) and colon cancer (C225, Erbitux).
From these clinical trials, it is abundantly clear that not all
patients positive for the EGFR respond to these targeted
therapeutics (Table 1). Determining factors that cause patients
to be susceptible to EGFR therapeutics is an important goal
from a patient welfare and economic point of view. Likewise,
understanding the nature of resistance to EGFR therapeutics
may help identify approaches for overcoming it.
Cancer Therapy: Preclinical
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Mechanisms causing resistance/susceptibility to EGFR-
targeted TKIs have been studied extensively, whereas factors
affecting the efficacy of anti-EGFR antibodies remain relatively
unknown (see Table 1). A few generalizations can be drawn
from these studies with respect to TKIs. First, the sensitivity of
cell lines to inhibition by TKIs correlates with increasing cell
surface EGFR (Table 1), suggesting that there is some intrinsic
level of EGFR expression required for these inhibitors to
function. Second, the ability to sustain signaling through
the phosphatidylinositol 3-kinase/Akt pathway following
EGFR inactivation reduces the efficacy of TKIs (Table 1). The
overwhelming number of these studies has been done in vitro;
thus, it is not known if these observations hold true in the
in vivo setting. Recently, several studies have analyzed the status
of the EGFR gene in lung cancer patients treated with Iressa
(ZD1839) and found that patients who responded to therapy
often had gain-of-function mutations in the kinase domain
(Table 1). Furthermore, a secondary kinase mutation that leads
to Iressa resistance has also been described (Table 1). Initial
studies suggest, however, that these observations are not
general and that the mutations described in lung patients are
not observed in other tumor types.
The limited number of studies using anti-EGFR antibodies
makes it difficult to derive any generalizations about suscep-
tibility to these agents (Table 1). Apart from the lack of in vivo
studies, many of these susceptibility studies have been done






PD153035 Multiple cell lines in vitro Sensitivity correlated with wt EGFR number No in vivo data (32)
C225 Renal cell carcinomas
in vitro
Only cells containing the VHL gene
were sensitive
No in vivo data (33)
EMD55900 and
EMD72000
Multiple cell lines in vitro
and xenografts
Sensitivity correlated with wt EGFR number (34)
SU1195 and
ZD1839
Multiple cell lines in vitro
and xenografts
More difficult to inhibit the phosphorylation




A431 xenografts Recurrent xenografts following complete
regression were often resistant to
further therapy
Overexpression of VEGF
was a common observation
in resistant cell lines
(36)
ZD1839 A431 and NR6M (express
the de2-7 EGFR)
xenografts
Xenografts expressing the de2-7 EGFR
were resistant
NR6M expresses the de2-7
EGFR in the absence of the
wt EGFR, clinically both are
coexpressed
(37)
AG1478 Glioma cell lines in vitro Resistant glioma expresses IGFR-I,
which is further up-regulated by
AG1478. IGFR-I effect seems
mediated through PI3K/Akt
Observation restricted to a
single cell line in vitro
(38)
CGP59326 BT474 breast and MKN7
gastric cancer cells in vitro
Activation of erbB2/3 heterodimers by
heregulin-generated resistance
No in vivo data (39)
ZD1839 Multiple cell lines in vitro Sensitivity correlated with wt EGFR number
Constitutive active MAPK increased resistance.
No in vivo data (40)
AG1478 Large cell panel in vitro Two requirements for sensitivity: high wt EGFR
and ability to respond to EGF by entering
cell cycle
No in vivo data (41)
ZD1839 and
PD153035
Multiple cell lines in vitro Sustained signaling through Akt or Erk may
cause resistance
No in vivo data (42)
ZD1839 A431 and MDA-468 breast
cancer cells in vitro
Sustained signaling through Akt causes
resistance. Presence of PTEN increases
effectiveness of EGFR therapeutics
No in vivo data (43)
ZD1839 and
C225
A431 and multiple NSCLC
in vitro
No correlation with EGFR number No in vivo data (44)
ZD1839 Patients with NSCLC Patients with activating mutations in the EGFR
kinase domain more likely to respond
Subsequent data suggest that
not all patients with
mutations respond
(28, 45)
ZD1839 NR6 fibroblasts and U87MG
glioma cells
Cells expressing the de2-7 EGFR were resistant,
possibly related to an inability to fully inhibit
de2-7 EGFR phosphorylation
No in vivo data (46)
OSI-774 Panel of glioma cell lines Cells capable of increasing the mRNA for EGFR in




Patients with NSCLC A secondary mutation in EGFR kinase causes
resistance
(48)
C225 and ABX Patients with colorectal
cancer
Response correlated with increase in EGFR
copy number
Small sample numbers (26)
OSI-774 and
ZD1839
Patients with glioma Coexpression of EGFRvIII and PTEN is associated
with responsiveness
(49)
Abbreviations: IGFR-I, insulin-like growth factor receptor-I; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase; Erk,
extracellular signal-regulated kinase; NSCLC, non–small cell lung cancer.
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using cell panels, which, given the variation in signaling
pathways between cell lines and the presence or absence of
other ErbB family members, makes it difficult to identify single
factors associated with EGFR sensitivity or resistance. To
address some of these issues, we tested the in vivo susceptibility
of the U87MG glioma cell line, which expresses modest levels
of the wild-type (wt) EGFR, to two EGFR-specific antibodies.
We then transfected U87MG cells with a variety of wt and de2-7
EGFR constructs to determine what effect receptor number and
activation has on susceptibility to antibody therapy.
The two antibodies used in this study are mAbs 806 and
528. MAb 806 is a novel anti-EGFR–specific antibody that was
raised against cells expressing the de2-7 EGFR (13). Interest-
ingly, although mAb 806 clearly binds the de2-7 EGFR, it also
binds to a subset of the wt EGFR (f10%) expressed on the
surface of cells overexpressing the receptor (13). Recent analysis
showed that the mAb 806 epitope is only exposed in a
conformational form of the EGFR that exists transiently as the
receptor moves from its inactive to active state (14). Unlike the
wt EGFR, the de2-7 EGFR is constitutively in this transitional
conformation and thus available for mAb 806 binding. Our
previous studies have shown that treatment of xenografts,
which express the de2-7 or overexpress the wt EGFR with mAb
806, causes significant inhibition of tumor growth (15–17).
The 528 antibody was produced and isolated at the same time
as the murine version of the C225 antibody (Erbitux) and
displays very similar properties (18). MAb 528 acts as a ligand
antagonist and inhibits the growth of EGFR-expressing cells
both in vitro and in vivo when grown as xenografts (18).
Materials andMethods
Cell lines and mAbs. The U87MG-transfected cell lines U87MG.D2-7,
U87MG.DK, U87MG.wt, U87MG.DY5, and U87MG.DY2 have been
described in detail elsewhere (16, 19). The A431 cell line has also been
described previously (20). All cell lines were maintained in either
DMEM (DMEM/F12; Life Technologies, Inc., Grand Island, NY) or
RPMI 1640 containing 10% FCS (CSL, Melbourne, Victoria, Australia),
2 mmol/L glutamine (Sigma Chemical Co., St. Louis, MO), and
penicillin/streptomycin (Life Technologies, Grand Island, NY). In
addition, transfected cell lines were maintained in 400 mg/mL geneticin
(Life Technologies, Inc., Melbourne, Victoria, Australia).
The mAbs 806 and 528 were produced and purified in the Biological
Production Facility (Ludwig Institute for Cancer Research, Heidelberg,
Melbourne, Australia). Antibodies to the specific tyrosine phosphory-
lation sites of the EGFR and a rabbit polyclonal anti-EGFR antibody
were obtained from Cell Signaling Technology (Danvers, MA). Src was
detected using the mouse mAbs v-Src 327 (Oncogene Research
Products, San Diego, CA) or c-Src H-12 (Santa Cruz Biotechnology,
Santa Cruz, CA). The rabbit polyclonal antibody PY418 (BioSource
International, Inc., Camerillo, CA) was used for the detection of
phospho-Src. The anti-phosphotyrosine antibody 4G10 was purchased
from Upstate Biotechnology (Lake Placid, NY). The C13 used for
detection of both wt and truncated EGFR was obtained from BD
Transduction Laboratories (San Diego, CA).
Generation of U87MG.D2-7DNSrc cell line. A dominant-negative,
kinase dead Src construct (K296R/Y528F) was obtained from Upstate
Biotechnology. A HindIII fragment containing the DNSrc was
subcloned into the pcDNA3.1/Hygro(+) vector obtained from Invi-
trogen Life Technologies (Carlsbad, CA) and the resulting construct was
transfected into U87MG.D2-7 cells by electroporation. A second cell
line transfected with the pcDNA3.1/Hygro vector alone was also
generated. Cells were plated out in 1 mL aliquots into 96-well plates, at
a density of approximately 2  104 cells per well, and incubated at
37jC for 48 h after which 100 Ag/mL hygromycin (Roche Diagnostics,
Mannheim, Germany) was added. Once clones were obtained (f2
weeks), cells were placed back in 400 Ag/mL geneticin as well as the
hygromycin.
Transfected cells were initially screened by fluorescence-activated cell
sorting analysis to confirm that expression of the de2-7 EGFR had been
retained. Clones were then subjected to either whole-cell lysis or
immunoprecipitation before Western blotting using Src-specific anti-
bodies (v-Src 327 and c-Src H-12). Several clones showing dramatically
increased levels of total Src (Src levels are very low in the original cell
line) were identified and expanded. The increased Src levels were
further confirmed by immunoprecipitating 35S-labeled cell lysates with
the v-Src 327 antibody and subjecting the resulting precipitates to
SDS-PAGE and quantitative autoradiography. The clone expressing the
highest levels of DNSrc was selected and the DNSrc was shown to be
phosphorylated at position Y418, suggesting that it is correctly folded.
In vitro growth assays. The antiproliferative effect of mAbs 806 and
528 in vitro was examined as described in detail previously (18). Briefly,
cells were seeded at 1  104 cells per well in 24-well plates in medium
containing 0.5% FCS. After 4 days, cells were removed with trypsin and
counted using a hemocytometer. Antibodies were used at a final
concentration of 100 Ag/mL, a concentration consistent with that
obtained within xenografts.
Xenograft models. Tumor cells (3  106) in 100 AL PBS were
inoculated s.c. into both flanks of 4- to 6-week-old, female nude mice
(Animal Research Centre, Perth, Western Australia, Australia). All
studies were conducted using established tumor models as reported
previously (15, 16). Treatment commenced once tumors had reached a
mean volume of f100 mm3. Tumor volume in cubic millimeter was
determined using the formula (length  width2) / 2, where length was
the longest axis and width being the measurement at right angles to the
length. Data are expressed as mean tumor volume F SE for each
treatment group. All data were analyzed for significance by Student’s
t test. A minimum of 10 xenografts per group were used in each study.
Immunoblotting. Cells were lysed in cold lysis buffer [30 mmol/L
HEPES, 150 mmol/L NaCl, 10 mmol/L NaF, 1% Triton X-100,
200 Amol/L NaO3V, 0.4% H2O2, the protease inhibitor cocktail set
1 (Calbiochem, San Diego, CA) containing 500 Amol/L AEBSF,
150 nmol/L aprotinin, 1 Amol/L E-64 protease inhibitor, 0.5 mmol/L
EDTA, and 1 Amol/L leupeptin (pH 7.4)]. Lysates were immunopre-
cipitated with the mAb 806 or 528, and the resultant precipitates were
analyzed by immunoblotting as described by us in detail (21).
Immunofluorescence microscopy. MAbs 806 and 528 were directly
labeled with Cyanine 3 (Cy3) dye using the Cy3 mAb Labeling kit
(Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, United
Kingdom) according to the manufacturer’s instructions. Successful
labeling of antibody was determined via flow cytometry analysis of
binding to U87MG.D2-7 cells. The early endosome-specific, antimouse
early endosome autoantigen 1 (EEA1) mAb was purchased from
Transduction Laboratories. Cyanine 2–conjugated AffiniPure F(ab¶)2
fragment donkey anti-mouse IgG secondary antibody and unlabeled
AffiniPure Fab fragment goat anti-mouse IgG blocking antibody were
purchased from Jackson ImmunoResearch Laboratories (West Grove,
PA). U87MG.D2-7 or NR6.D2-7 cells were grown on 12 mm glass
coverslips or 12 mm Biocoat Cell Environments Poly-L-Lysine coverslips
(Becton Dickinson Labware, Bedford, MA) in MEM (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine serum,
penicillin/streptomycin, and glutamate at 37jC. Antibody binding to
cells was carried out in the presence of 0.25% bovine serum albumin
(Sigma Chemical). Cy3-conjugated mAbs 806 and 528 were used at
concentrations of 5 and 2 Ag/mL, respectively, and surface labeling was
carried out at 4jC for 20 min under humidified conditions. Cells were
washed thrice in ice-cold 0.25% bovine serum albumin/PBS. Interna-
lization of surface-bound antibody was initiated by incubation of
individual coverslips at 37jC. Following internalization for varying
periods, individual coverslips were removed from 37jC, washed thrice
Targeting EGFR in Glioma
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in ice-cold bovine serum albumin/PBS to stop internalization, and
fixed in 4% paraformaldehyde for 20 min at room temperature.
Coverslips were then washed in bovine serum albumin/PBS before
washing in double-distilled water and mounted onto glass slides with
fluoromount G mounting medium (Southern Biotechnology, Birming-
ham, AL). Samples were analyzed with confocal microscope (Nikon
Instech Co. Ltd., Kanagawa, Japan) using appropriate wavelength
settings. For colocalization studies, cells were permeabilized with 0.1%
Triton X-100 for 1 min. Samples were then washed and incubated with
unlabeled goat anti-mouse Fab fragment to block all existing mouse
binding sites (i.e., internalized mAb 806 or 528) for 20 min at room
temperature. Samples were then washed in bovine serum albumin/PBS
before incubation with anti-EEA1 for 20 min at room temperature.
Cells were finally washed and incubated with cyanine 2–conjugated
secondary donkey anti-mouse F(ab¶)2 antibody fragment. DNA vectors
for green fluorescence protein (GFP)–tagged lysosomal glycoprotein
120 (lgp-120-GFP) was kindly provided by Prof. Ira Mellman and
professor from the Department of Cell Biology, Yale University School
of Medicine (New Haven, CT). Cells grown in MatTek glass bottom
microwell dishes containing an embedded 14 mm glass coverslip
(MatTek Corp. Ashland, MA) were transfected overnight using
LipofectAMINE reagent (Invitrogen Life Technologies, Mulgrave,
Victoria, Australia) following the manufacturer’s instructions. Confocal
imaging of positively transfected cells, which fluoresced green when
excited with 488 nm wavelength light, was undertaken 24 h after
transfection.
Results
Correlation between in vitro and in vivo sensitivity. Many of
the studies described in Table 1 have been conducted in vitro.
Our experience with both mAb- and TKI-targeted EGFR therapy
clearly shows that in vitro sensitivity and in vivo response do not
reliably correlate. Indeed, we published recently an example
where two cell lines showing similar sensitivity to the EGFR-
specific TKI AG1478 in vitro differed notably in their in vivo
response to the same agent (22). Using a standard in vitro
growth inhibition assay described previously for C225, and an
antibody concentration consistent with that achieved at the
xenograft site, we saw little correlation between antibody
inhibition in vitro and in vivo antitumor activity (Table 2).
Neither mAb 528 or 806 inhibited the growth of U87MG.D2-7
cells in vitro , but both antibodies display robust antitumor
activity in vivo that was independent of immune effector
function (see Fig. 2). In addition, even if one EGFR-targeted
antibody showed correlation in vitro and in vivo in a particular
cell line (e.g., mAb 528 in A431 cells and xenografts; Table 2),
this did not necessarily imply that another EGFR-specific
antibody will correlate in the same cell line (e.g., mAb 806 in
A431 cells and xenografts; Table 2). This simple analysis, along
with our previous observations clearly, shows the limited
value of in vitro assays in determining sensitivity to EGFR
therapeutics.
Antibody therapy of U87MG glioma xenografts expressing
different forms of the EGFR. The parental U87MG cells, which
express moderate levels of the wt EGFR, or the same cell line
transfected with additional wt EGFR, the de2-7 EGFR or various
modified forms of the de2-7 EGFR (Fig. 1) were injected s.c.
into nude mice and allowed to establish as tumor xenografts.
Treatment with antibody commenced once xenografts had
reached f100 mm3. All tumors were treated with 1 mg mAb
528 or 806 thrice weekly for 2 weeks. This dose and schedule of
antibody treatment was chosen as it elicits a strong antitumor
response in our standard U87MG.D2-7 xenograft model but is
not so efficacious that it would obscure any increased
antitumor activity that might be seen in other U87MG-derived
cell lines containing different variants of the EGFR. As discussed
in detail below, the antitumor efficacy of mAbs 806 and
528 was similar in all the U87MG-derived glioma xenografts
(Fig. 2).
(a) Parental cells (U87MG): neither antibody inhibited the
growth of the U87MG xenografts despite the fact that it
expresses the EGFR at moderate levels (approximately 5 
104 receptors per cell; ref. 13).
(b) Cells overexpressing the wt EGFR (U87MG.wt): transfec-
tion of U87MG cells with the wt EGFR to increase expression
(approximately 1  106 receptors per cell) did not change the
in vivo growth rate of the xenografts (Fig. 3A) but caused the
tumors to become sensitive to both antibodies. Although this
is not surprising for mAb 806, as it preferentially binds to
cells overexpressing the wt EGFR, it was somewhat unex-
pected for mAb 528, as it suggests that even an increase in
receptor number in the absence of a phenotypic change
can induce a response to antibody therapy. On day 31, when
the control group was sacrificed, the inhibition induced by
mAb 528 was significant (P < 0.01), with xenografts in the
vehicle group having a mean tumor volume of 950 mm3
compared with 450 mm3 in the mAb 528 treatment group.
Analysis of the mAb 806 experiment on day 39 showed that
antibody treatment significantly inhibited xenograft growth
(P < 0.001) with tumor volumes being 960 and 470 mm3 for
the PBS and mAb 806, groups, respectively.
(c) Cells expressing the de2-7 EGFR (U87MG.D2-7): the
growth of U87MG xenografts transfected with the constitu-
tively active, but ligand-independent, de2-7 EGFR was also
inhibited by both antibodies (Fig. 2). Unlike overexpression
of the wt EGFR, coexpression of the de2-7 EGFR in the
presence of endogenous wt EGFR generates a significant
growth advantage to U87MG xenografts (Fig. 3B). The
constitutive phosphorylation of this receptor was confirmed
by immunoblotting (Fig. 4). Treatment with mAb 528
significantly inhibited tumor growth (P < 0.005) with the
vehicle group having an average tumor volume of 1,170 mm3
compared with 510 mm3 for the mAb 528 group at day 20
postinoculation. Given that the primary function of mAb 528
has been presumed to be ligand antagonism, its antitumor
activity against a xenograft expressing the ligand-independent
de2-7 EGFR was unexpected. Thus, mAb 528 probably
disrupts EGFR signaling by other mechanisms apart from
its ability to block ligand. Likewise, mAb 806, which only
Table 2. In vitro and in vivo comparison of
sensitivity to EGFR therapeutics
Cell line
U87MG.#2-7 A431
mAb 528 mAb 806 mAb 528 mAb 806
In vitro   + 
In vivo* + + ++ ++
*In vivo data for A431 xenografts from Perera et al. (16).
Cancer Therapy: Preclinical
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binds the de2-7 EGFR and not the wt EGFR in these cells,
must mediate its antitumor activity independent of any effect
on ligand interaction as it inhibited the growth of de2-7
EGFR–expressing xenografts to a similar level as mAb 528. At
day 21, when the vehicle group was culled, the control
xenografts had a mean tumor volume of 1,500 mm3
compared with a significantly lower 390 mm2 in the mAb
806–treated group (P < 0.0001). Thus, both antibodies can
inhibit glioma xenografts expressing a ligand-independent
but constitutively active form of the EGFR.
(d) Cells expressing a dead kinase (DK) version of the de2-7
EGFR (U87MG.DK): U87MG cells transfected with a DK
version of the de2-7 EGFR grew as xenografts at a rate similar
to parental cells (Fig. 3B) and were not significantly inhibited
by either antibody (Fig. 2). This receptor lacks phosphory-
lation at the major sites associated with signaling but remains
phosphorylated at sites associated with receptor internaliza-
tion and degradation (Fig. 4). Binding of both antibodies to
these cells is similar to that seen in de2-7 EGFR–expressing
cells both in vitro and in vivo (16). Furthermore, because the
DK variant of the de2-7 EGFR only contains a single
intracellular point mutation, the affinity of mAbs 806 and
528, which bind the extracellular domain, should not be
altered. This result shows that any immune effector function
mediated by these antibodies in vivo is insufficient to initiate
an antitumor response. Furthermore, it shows that the
antitumor activity of anti-EGFR antibodies require a receptor
with a functional kinase domain.
(e) Cells expressing a version of the de2-7 EGFR with
deletion of two major sites for autophosphorylation
(U87MG.DY2): U87MG xenografts expressing a de2-7 EGFR
construct unable to autophosphorylate at two major auto-
phosphorylation sites (Tyr1068 and Tyr1173 changed to
phenylalanine) were significantly inhibited by both anti-
bodies when grown as tumor xenografts (P < 0.01 and 0.006
for mAbs 528 and 806, respectively; Fig. 2). This observation,
combined with the lack of activity seen against the
U87MG.DK xenografts, suggests that the kinase activity, as
opposed to autophosphorylation, correlates with responsive-
ness to antibody therapy.
Fig. 1. Schematic representation of the EGFR.
The extracellular region deleted in the de2-7 EGFR is
identified by parenthesis.The DKversion of the de2-7
EGFR contains a single point mutation (K!M) at
position 721.The DY2 version of the de2-7 EGFRhas
Y!F mutations at residues1068 and1173, whereas the
DY5 variant also has these substitutions plus 992,1086,
and1148. *, tyrosine residues mutated in DY5; #,
tyrosine residues mutated in DY2.
Targeting EGFR in Glioma
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(f) Cells expressing a version of the de2-7 EGFR incapable of
autophosphorylation (U87MG.DY5): U87MG cells express-
ing a de2-7 EGFR construct unable to autophosphorylate at
all five major autophosphorylation sites associated with
signaling (Tyr1173, Tyr1148, Tyr1086, Tyr1068, and Tyr992
changed to phenylalanine) were grown as tumor xenografts.
This receptor lacks phosphorylation at the major sites
associated with signaling but remains phosphorylated at
Fig. 2. Sensitivity of different xenografts to
EGFR-specific antibodies. Xenografts were
established by injection of 3 106 cells in
both flanks of nude BALB/c mice. Antibody
therapy commenced when xenografts
reached an approximate mean volume of
100 mm3. Mice were treated with1mgmAb
528 (left) or mAb 806 (right) thrice weekly
for 2 wks (i.e., a total of six injections).
Points, mean tumor volume; bars, SE.
Cancer Therapy: Preclinical
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sites associated with receptor internalization and degradation
(Fig. 4). Consistent with the result obtained with DY2 xeno-
grafts, both antibodies significantly inhibited the growth
of xenografts expressing the DY5 de2-7 EGFR construct
(P < 0.0001 for both antibodies; Fig. 2). Given this somewhat
unexpected result, we repeated this experiment with both
antibodies, at a lower dose (0.5 versus 1 mg per injection),
and once again obtained significant inhibition of tumor
growth in both cases (data not shown). Because the DY5
form of the de2-7 EGFR is incapable of directly binding
adapter molecules critical for downstream signaling, it
suggests that an active kinase domain rather than the
interaction with these molecules is a critical feature that
leads to responsiveness to EGFR-specific antibodies.
Treatment of U87MG xenografts expressing high levels of the
de2-7 EGFR. The data in Fig. 2 suggest that the more
dependent a xenograft becomes to EGFR signaling the more
likely it is to respond to EGFR-specific antibody therapy.
Therefore, using fluorescence-activated cell sorting, we isolated
the cells expressing very high levels of the de2-7 EGFR
(U87MG.D2-7high; Fig. 5A). U87MG.D2-7high xenografts grew
faster than the original U87MG.D2-7 xenografts (Fig. 5B),
suggesting that the rapid growth of these xenografts is reliant
on the high levels of the de2-7 EGFR. The levels of de2-7 EGFR
expression were retained in vivo as determined by immuno-
blotting of xenograft lysates (Fig. 5C). Treatment with mAb 806
or 528 caused significant inhibition of U87MG.D2-7high
xenografts that was greater than that observed for any other
of the U87MG-derived cell lines (Fig. 5D). On day 18, when the
control group was sacrificed for ethical reasons, the mean
tumor volume was 1,760, 90, and 90 mm3 for the vehicle, mAb
806, and mAb 528 groups, respectively (P < 0.001). Signifi-
cantly, although there were no complete regressions in any
of the previous U87MG-derived therapy studies (Fig. 2), 40%
of the mAb 806–treated and 20% mAb 528–treated U87MG.
D2-7high xenografts completely regressed. One of the mAb 806
tumors recurred at day 46 postinoculation, whereas other
tumors had not recurred by day 126 when the mice were
sacrificed. Thus, xenografts driven by the overexpression of a
constitutively active form of the EGFR are more sensitive to
EGFR-specific antibodies.
mAbs 806 and 528 therapy of established NR6-derived
xenografts. The NR6 murine fibroblastic cell line does not
endogenously express any members of the ErbB family (23),
an observation we confirmed by fluorescence-activated cell
sorting for EGFR, ErbB2, and ErbB3 (data not shown). These
cells were then stably transfected with human de2-7 EGFR
(NR6.D2-7). Because all the U87MG-derived cell lines used to
test the efficacy of mAbs 806 and 528 against the de2-7 EGFR
also coexpress the wt EGFR, we assessed their therapeutic
efficacy in mice with established NR6.D2-7 xenografts. MAb
806 treatment resulted in a reduction in overall tumor growth
rate compared with treatment with vehicle that was highly
Fig. 3. Xenograft growth curves for U87MG-based cell lines. Xenografts were
established by injection of1106 cells in both flanks of nude BALB/c mice in order
to determine growth curves. Points, mean tumor volume; bars, SE.
Fig. 4. In vitro phosphorylation of de2-7 EGFRVariants in U87MG.D2-7,
U87MG.DK, and U87MG.DY5 cells. A, the de2-7 EGFR protein was
immunoprecipitated (IP) with mAb 806, mAb 528, or an irrelevant
isotype-matched control antibody, and resulting samples were immunoblotted (IB).
All de2-7 EGFR variants were positive for phosphorylation atY1045, the major site
associatedwith ubiquitination and degradation (top).Whereas the de2-7 EGFRwas
constitutively phosphorylated at positionY1173, both the DK and DY5 variants were
negative for phosphorylation at this site as expected (middle).The presence of
EGFR was confirmed using the rabbit COOH-terminal polyclonal antibody to the
EGFR (bottom).This COOH-terminal antibody did not recognize the DY5 variant
because it contains aY1068F mutation, which turns out to be a critical residue for
antibody binding.Thus, the presence of total DY5 protein was confirmed in (B) by
immunoblotting with mAb 806.
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significant at day 42 postinoculation (P < 0.003; Fig. 6). The
average tumor volume on the final day of therapy (day 39) was
1,520 and 670 mm3 for the vehicle and mAb 806 treatment
groups, respectively (Fig. 6A).
Mice bearing established NR6.D2-7 xenografts were also
treated with mAb 528. On day 56 postinoculation, when
animals were killed for ethical reasons, the size of tumors
treated with mAb 528 did not differ from that of vehicle-treated
xenografts (Fig. 6B). We conducted a second therapy experi-
ment with mAb 528 using a slightly varied protocol whereby
mice received antibody twice weekly for 3 weeks. Once again,
mAb 528 failed to inhibit the growth of established NR6.D2-7
xenografts under these conditions (Fig. 6C). Thus, unlike mAb
806, mAb 528 is unable to inhibit xenografts expressing the
de2-7 EGFR in the absence of the wt EGFR.
Src activity modulates the responsiveness of de2-7 EGFR–
expressing xenografts to antibody therapy. Because mAbs 806
and 528 inhibit xenografts expressing the DY5 version of the
de2-7 EGFR and because neither antibody decreases de2-7
EGFR phosphorylation as a single agent in vivo (16), it is likely
that these antibodies mediate their antitumor activity by
disrupting the transphosphorylation of a target downstream
of the de2-7 EGFR. Our observations with the NR6.D2-7
xenografts suggest that the antitumor activity of mAb 528 is
dependent on the coexpression of the de2-7 EGFR with another
member of the ErbB family, whereas mAb 806 activity is
independent of this interaction. Therefore, we examined if the
de2-7 EGFR could interact with Src, as is the case for the wt
EGFR, and if this potential interaction is related to mAb 806
efficacy.
Activation of the wt EGFR leads to the transient activation of
Src kinase. In a synergistic manner, activation of Src leads to
phosphorylation Tyr845 (Y845) on the EGFR, which is not an
autophosphorylation site rather a target for Src phosphoryla-
tion (24). Using an antibody specific to Y845, we examined the
phosphorylation of Y845 in the de2-7 EGFR. When expressed
in U87MG glioma cells, the de2-7 EGFR showed robust
phosphorylation of Y845 (Fig. 7A). Phosphorylation at Y845
was rapidly blocked by incubating cells with PP1 and PP2,
inhibitors of the Src-family kinases, whereas the autophospho-
rylation site at Y1173 was relatively unaffected (Fig. 7A).
Given that the de2-7 EGFR seems to be a target for Src kinase
phosphorylation in a manner analogous to that of the wt
EGFR, we sort to determine if this interaction was critical to
mAb 806 activity. Initially, we constructed a de2-7 EGFR
containing a Y845F substitution; however, this protein showed
reduced phosphorylation at multiple sites4 and was therefore
Fig. 5. U87MG cells expressing high levels of de2-7 EGFR. U87MG.D2-7 cells were FACS sorted into low (L), medium (M), and high (H) expressing populations. A, cells
were lysed following 36 h of serum starvation and analyzed by immunoblotting for de2-7 expression (C13) and tyrosine phosphorylation (4G10) of the de2-7 EGFR. Levels of
phosphorylation correlated with de2-7 EGFR. B, parental U87MG, U87MG-L, U87MG-M, and U87MG-H xenografts were established by injection of1 106 cells in both
flanks of nude BALB/c mice in order to determine growth curves. Points, mean tumor volume; bars, SE. C, tumors from (B) were analyzed by immunoblotting for expression
of de2-7 EGFR (C13). D, mice with U87MG-H xenografts were treated with1mg mAb 528 or 806 thrice weekly for 2 wks (d 4, 6, 8, 11, 13, and15). Points, mean
tumor volume; bars, SE.
4 T.G. Johns, unpublished observation.
Cancer Therapy: Preclinical
www.aacrjournals.orgClin Cancer Res 2007;13(6) March15, 2007 1918
 American Association for Cancer Research Copyright © 2007 
 on August 24, 2011clincancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/1078-0432.CCR-06-1453
considered unsuitable for these studies. Thus, as described in
Materials and Methods, we developed a U87MG cell line
coexpressing the de2-7 EGFR and a DNSrc (U87MG.D2-7DNSrc).
U87MG.D2-7DNSrc xenografts grew as tumor xenografts in nude
mice but at a rate slower than U87MG.D2-7 transfected with a
vector control (Fig. 7B). Treatment of U87MG.D2-7DNSrc with
mAb 806 resulted in robust inhibition of tumor growth
(Fig. 7C). At day 34 postinoculation, the average xenograft
volume was 1,220 mm3 in the vehicle group compared with
100 mm3 in the mAb 806–treated group (P < 0.001; Fig. 7C).
Furthermore, 60% of all U87MG.D2-7DNSrc xenografts in the
mAb 806–treated group completely regressed and had not
recurred by day 50 postinoculation. Thus, inhibition of Src
signaling seems to increase the efficacy of mAb 806 therapy
(Fig. 2; Fig. 7C).
Internalization of mAb 806 in U87MG.D2-7 cells. The
intracellular trafficking of mAb 806 following binding to de2-
7 EGFR expressed in U87MG.D2-7 cells was investigated by
confocal microscopy. Following incubation of mAb 806-Cy3 at
4jC and before chase at 37jC, mAb 806 bound to de2-7 EGFR
Fig. 6. Treatment of NR6.D2-7 xenografts with EGFR-specific antibodies.
Xenografts were established by injection of 3  106 cells in both flanks of nude
BALB/c mice. Antibody therapy commenced when xenografts reached an
approximate mean volume of100 mm3. Mice were treated with1mg mAb 806 (A)
or mAb 528 (B) thrice weekly for 2 wks (days 22, 25, 29, 32, 36, and 39) or
with mAb 528 (C) twiceweekly for 3 wks (days 27, 30, 34, 37, 41, and 44). Points,
mean tumor volume; bars, SE.
Fig. 7. Interaction between de2-7 EGFR and Src. A, cells were serum starved
overnight before treatment with10 Amol/L PP1or PP2 or vehicle (DMSO) for
30 min or 24 h before immunoprecipitation with mAb 528, mAb 806, or an
irrelevant isotype control. Immunoblotting (WB) was done with an antibody
specific forY845 of the EGFR, whereas total de2-7 EGFR was visualized with the
rabbit COOH-terminal polyclonal antibody. Results are representative of four
independent experiments. B, U87MG.D2-7vector control and U87MG.D2-7DNSrc
xenografts were established by injection of1 106 cells in both flanks of nude
BALB/c mice in order to determine growth curves. Points, mean tumor volume;
bars, SE. C, U87MG.D2-7DNSrc xenografts were established by injection of 3  106
cells in both flanks of nude BALB/c mice. Antibody therapy commenced when
xenografts reached an approximate mean volume of 100 mm3. Mice were treated
with1mgmAb 806 thrice weekly for 2 wks (days18, 20, 22, 25, 27 and 29).
Points, mean tumor volume; bars, SE.
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was located along the plasma membrane (Fig. 8A, 0 min, mAb
806-Cy3). Following incubation at 37jC, mAb 806 (Fig. 8A,
mAb 806-Cy3) was observed to translocate to small, punctate,
cytoplasmic vesicles. Subsequent immunostaining with anti-
EEA1, which identifies early endosomes (Fig. 8A, EEA1),
showed partial colocalization with mAb 806 as visualized by
the presence of yellow fluorescence (Fig. 8A, Merge). Following
60 min of chase at 37jC, the colocalization was minimal
(Fig. 8A, Merge, 60 min), suggesting that the majority of
antibody has moved out of early endocytic compartments.
These observations indicate that mAb 806 localizes to early
endocytic compartments immediately following internalization
before moving to an alternative location later in its intracellular
trafficking cycle.
Lysosomal localization of mAb 806 following binding and
internalization of de2-7 EGFR in U87MG.D2-7 cells was
accomplished via colocalization analysis in cells transiently
transfected with lgp-120-GFP (Fig. 8B). Cells positively trans-
fected for lgp-120-GFP displayed cytoplasmic perinuclear green
fluorescence consistent with localization to lysosomal compart-
ments as expected (Fig. 8B, lgp-120-GFP). Before induction of
internalization, mAb 806-Cy3 was only detected on the cell
surface (Fig. 8B, 0 min, mAb 806-Cy3) and did not colocalize
with lgp-120-GFP (Fig. 8B, 0 min, Merge). Following warming
to 37jC for 30 min, small intracellular vesicular structures
corresponding to internalized mAb 806 were observed (Fig. 8B,
30 min, mAb 806-Cy3). Some of these structures colocalized
with lgp-120-GFP; however, the majority of red and green
signal remained segregated (Fig. 8B, 30 min, Merge). Longer
incubation at 37jC for 60 and 120 min resulted in increased
colocalization of internalized mAb 806-Cy3 and lgp-120-GFP
(Fig. 8B, 60-120 min, Merge). These observations are consistent
with the hypothesis that mAb 806 initially traverses through
early endocytic compartment but after longer periods moves
into lysosomal compartments where it accumulates.
The internalization of mAb 806 following binding to the
de2-7 EGFR expressed on U87MG.D2-7 cells was also analyzed
by electron microscopy. Following 5 min of incubation at
37jC, gold particles, corresponding to mAb 806, were observed
in structures resembling clathrin-coated pits (Fig. 9A and B).
Gold particles were also detected in free clathrin-coated vesicles
located within the cytoplasm (Fig. 9C). No gold particles were
Fig. 8. Colocalization of internalized mAb 806-Cy3 and EEA1or lgp-120 in U87MG.D2-7 cells. A, cells seeded on glass coverslips were preincubated with mAb
806-Cy3 (red) at 4jC (0min). Internalizationwas stimulated by incubation at 37jC for10, 20, and 30min. Cells were fixed and permeabilized and then stainedwith anti-EEA1
followed by Cy2-conjugated donkey anti-mouse antibody (green). Colocalization (yellow in the merged images, arrows). Bar, 20 Am. B, cells were transiently transfected
with lgp-120 tagged with GFP (lgp-120-GFP; green). Positively transfected cells (lgp-120-GFP, green arrowheads). Following transfection, cells were incubated with mAb
806-cy3 at 4jC (red ; 0 min), before induction of internalization by incubating at 37jC for 30, 60, and120 min. Samples were subsequently fixed. Colocalization of mAb
806-Cy3 and lgp-120-GFP (yellow in the merged images, white arrows). Bar, 10 Am.
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observed in structures resembling caveolae (Fig. 9D). Following
10 min of chase at 37jC, mAb 806 localized to large tubular-
vesicular structures resembling early endocytic compartments
(Fig. 9E). Longer chase periods of 30 min resulted in antibody
localization in structures resembling multivesicular bodies
(Fig. 9F). These observations are consistent with the immuno-
fluorescence microscopy data that indicated colocalization of
mAb 806 with lgp-120 between 30 and 60 min.
Internalization of mAbs 806 and 528 in NR6.D2-7 cells.
Given the differences in therapeutic efficacy of mAbs 806 and
528 against NR6.D2-7 xenografts, the internalization character-
istics of each antibody was investigated in this cell line.
Furthermore, because NR6.D2-7 cells do not express any
endogenous members of the ErbB family, this cell line can
determine if the presence of wt EGFR is required for
internalization of these antibodies. Cells incubated with mAb
806-Cy3 at 4jC showed membrane staining with no intracel-
lular fluorescence as expected (Fig. 10, left, mAb 806, 0 min).
In contrast to U87MG.D2-7 cells (Fig. 8), membrane staining
was not uniform. More intense staining was associated with
membrane junctions between cells (Fig. 10, left, mAb 806,
0 min) and focal adhesions (Fig. 10, left, mAb 806, 0 min).
Some cells showed very little membrane staining (Fig. 10, left,
mAb 806, 0 min). Following induction of internalization by
raising the temperature to 37jC, characteristic intracellular
punctate vesicular structures were observed. These accumulated
in a perinuclear pattern (Fig. 10, left, mAb 806, 15-60 min)
consistent with rapid lysosomal localization. Initial localization
(Fig. 10, right, mAb 528, 0 min) and subsequent internalization
(Fig. 10, right, mAb 528, 15-60 min) of mAb 528 was identical
to that of mAb 806. Thus, both antibodies were rapidly
internalized to the lysosomal compartment following binding
to the de2-7 EGFR even in the absence of the wt EGFR.
Discussion
mAb 528. Many, but not all, previous studies have suggested
that EGFR number on the cell surface is one factor that
influences the efficacy of EGFR-targeted therapeutics, especially
TKIs (Table 1). However, these experiments have always
compared antitumor activity using different cell lines and thus
are not controlled with respect to genetic background, the
presence of other ErbB family members, and the occurrence of
other functional receptors/kinases capable of modulating the
EGFR signaling pathway. Furthermore, many of these studies
have been conducted in vitro , which we have shown does not
correlate with in vivo activity. Increasing the wt EGFR number
10-fold converts U87MG glioma xenografts from mAb 528
resistant to antibody responsive. Because the increase in wt
EGFR number did not alter the growth rate of the U87MG
xenografts, the advent of antitumor activity was not simply the
result of mAb 528 inhibiting an induced growth advantage. The
presence of more wt EGFR within U87MG.wtEGFR xenografts
would almost certainly lead to increased antibody localization
at the tumor site. Given that mAb 528 possesses low, but
measurable, immune effector function (25), the increased level
of antibody at the tumor site may result in increased
complement deposition and recruitment of immune cells that
contribute to inhibition of tumor growth. However, a role for
immune effector function in initiating the antitumor activity of
mAb 528 seems unlikely given our data with the U87MG.DK
xenografts. These xenografts have as many mAb 528 binding
sites as the U87MG.wtEGFR xenografts but are not inhibited by
the antibody. One intriguing possibility is that overexpression
of the wt EGFR leads to ligand-independent EGFR signaling
(the parental U87MG seems not to have a strong autocrine
ligand loop), which in turn causes the cells to become more
dependent on the EGFR signaling system. Thus, U87MG.
wtEGFR xenografts respond to mAb 528 therapy because,
unlike the parental cell line, the EGFR signaling pathway is
active and functional. Therefore, overexpression of the wt EGFR
is a surrogate marker of cells dependence on EGFR signaling
and therefore such cells are more likely, but not guaranteed, to
respond to EGFR therapeutics (26).
It has been presumed that the antitumor activity of anti-
bodies, such as mAb 528, is predominantly mediated by their
ability to antagonize ligand activation of the EGFR. Given that
mAb 528 inhibited the growth U87MG.wtEGFR xenografts in
the absence of significant ligand expression suggests that other
mechanisms may contribute to the antitumor effect. Further-
more, mAb 528 displayed significant efficacy against xenografts
expressing the ligand-independent de2-7 EGFR. This antitumor
activity could not directly result from mAb 528 binding the
Fig. 9. Electron microscopic analysis of clathrin-mediated endocytosis and
intracellular trafficking of mAb 806 following binding to de2-7 EGFR in
U87MG.D2-7 cells. Gold particles (mAb 806-Au; arrowheads) were readily
detected in clathrin-coated pits (A and B) and vesicles (C) following induction of
internalization for 5 min. No gold particles were present in structures resembling
caveolae (open arrowheads) (D). After10 to15 min of internalization, gold particles
were detected in tubular vesicular structures resembling early endosomes (E).
After longer periods of internalization, gold particles were seen in multivesicular
bodies (F). Bar, 100 nm.
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endogenous wt EGFR coexpressed in these xenografts, as it did
not inhibit the growth of parental U87MG or U87MG.DK
xenografts, both of which express identical levels of the wt
EGFR. Excluding immune effector function, alternate antitumor
mechanisms could include receptor down-regulation, induction
of inappropriate signaling, translocation of the receptor to
unsuitable membrane domains, and interference with receptor
dimerization and/or oligomerization. Indeed, some TKIs
directed to the EGFR not only function by inhibiting
kinase activity but also induce inactive dimers capable of
‘‘mopping’’ up excess ligand, an unanticipated antitumor
mechanism (27).
Interestingly, a recent immunohistochemistry study analy-
zing EGFR expression in colon patients showing differential
response to C225 reported that several patients ‘‘negative’’ for
EGFR had clinical responses to this EGFR-specific antibody
(26). Presumably, these patients have levels of EGFR below the
detection sensitivity of immunohistochemistry, yet the EGFR
present is activated and contributes to tumor growth/survival.
This observation suggests that EGFR activation is at least as
important, if not more so, than simply the level of EGFR
expression. Our data showing that mAb 528 did not inhibit the
growth of U87MG xenografts expressing a DK version of this
truncated receptor (U87MG.DK) support the view that the
efficacy of EGFR-specific antibodies is intimately associated
with kinase active receptors. As suggested above, EGFR over-
expression represents one mechanism by which this activation
can occur; the expression of a constitutively active mutant, such
as the de2-7 EGFR, denotes another. This continuous activation
of the EGFR causes cells to become ‘‘addicted’’ to EGFR
signaling, which in turn makes them susceptible to anti-EGFR
therapy. This concept is analogous to the situation in lung
cancer patients, where most patients who respond to EGFR-
specific TKIs carry activating mutations in the EGFR kinase
domain (28).
The ability of mAb 528 to inhibit the growth of U87MG.DY2
or DY5 xenografts highlights the significance of an active kinase
domain as opposed to autophosphorylation as a determinant
of efficacy. Thus, it is an active kinase that determines the
response to antibody therapy, not the direct interaction of
phosphorylated tyrosines with adapter or signaling molecules.
One corollary to this result is that mAb 528 seemingly inhibits
the growth of U87MG.D2-7/DY2/DY5 xenografts by preventing
the transphosphorylation of a downstream target (Fig. 11).
Because all these U87MG-derived cell lines coexpress the wt
EGFR, and given that we showed recently that the de2-7 EGFR
can form dimers and phosphorylate the wt EGFR (29), the wt
EGFR is a likely candidate for this secondary target. This
proposition is supported by the fact that NR6 cells expressing
the de2-7 EGFR in the absence of the wt EGFR were completely
refractory to the antitumor effects of mAb 528. Taken together,
these studies suggest that, along with its ligand blocking
properties, mAb 528 functions in part by preventing the
homodimerization of the overexpressed wt EGFR and hetero-
dimerization between the wt and de2-7 EGFR. Interestingly, the
structure of C225 (an antibody very similar to mAb 528) in
complex with the EGFR suggests that, apart from ligand
blockade, this antibody may prevent EGFR dimerization by
partially inhibiting EGFR untethering (30).
mAb 806. Responsiveness of U87MG-derived cell lines
in vivo to mAb 806 completely mirrored that observed with
mAb 528, indicating that many of the above principles apply,
although there are some important differences. This study
confirms and extends our previous studies showing that mAb
806 reactivity is associated with EGFR activation (16). Unlike
mAb 528, and all current antibodies in clinical evaluation, mAb
Fig.10. InternalizationofmAbs 806 and 528 inNR6.D2-7 cells. Cells were preincubatedwithmAb 806-Cy3 (left) ormAb 528-Cy3 (right) at 4jC (0min), before incubation
at 37jC for varyingperiods of time to induce internalization. Images representing15, 30, and 60min of incubation at 37jC. Stainingwith both antibodies before internalization
was associated with membrane junctions between cells (blue arrowhead) and focal adhesions (red arrowhead), whereas some cells showed very little membrane staining
(yellow arrowhead). Internalized antibody at later time points (white arrows). Bar, 20 Am.
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806 does not target normal tissue, such as the liver, as EGFR
activation is extremely low or nondetectable in organs, such as
the liver. A myriad of factors can stimulate EGFR activation
within tumors (see ref. 31 for a review). We have confirmed
that at least three of these, EGFR overexpression (15), mutation
(17), and presence of an autocrine loop,5 can lead to mAb 806
reactivity. The association of wt EGFR overexpression for mAb
806 antitumor activity is intimately related to its unique
specificity as overexpression increases the transient, untethered
form of the EGFR recognized by mAb 806, through multiple
mechanisms, such as ligand-independent activation and
alterations in EGFR glycosylation (21). Given that the work
described here, along with the clinical data obtained with
EGFR-specific TKIs, suggests that EGFR inhibitors are most
effective against tumors with an activated EGFR, the unique
ability of mAb 806 to specifically recognize activated forms of
the EGFR makes it an advantageous therapeutic.
Molecular modeling suggests that mAb 806 binding would
prevent the formation of active wt EGFR dimers (14), a
hypothesis we have confirmed by solving the crystal structure of
mAb 806 in complex with its epitope.5 Despite this, mAb 806
does not significantly inhibit the phosphorylation of the de2-7
or wt EGFR in xenograft models (16), strongly suggesting that
any proposed mechanism of action for mAb 806 includes more
than blockade of autophosphorylation. Furthermore, known
downstream targets of EGFR signaling, such as Akt and MAPK,
are also not inhibited by mAb 806.4 Consistent with this
hypothesis, mAb 806 displayed robust antitumor activity
against U87MG.DY2/DY5 xenografts, two models where
autophosphorylation is not pertinent. The lack of mAb 806
efficacy against U87MG.DK xenografts emphasizes that the
presence of an active kinase and transphosphorylation events
(Fig. 11) are critical factors leading to sensitivity. In contrast to
mAb 528, mAb 806 was able to inhibit the growth of NR6 cells
expressing the de2-7 EGFR in the absence of other ErbB family
members. This result indicates that mAb 806 potentially
disrupts other targets of de2-7 EGFR transphosphorylation,
distinct from the wt EGFR. Interestingly, there was no obvious
difference in the internalization and intracellular tracking of
mAbs 806 and 528 following binding of either antibody to
surface de2-7 EGFR in NR6 cells, suggesting that antibody
trafficking did not contribute to the difference in efficacy in this
xenograft model.
We report here for the first time that Y845 is phosphorylated
on the de2-7 EGFR in a Src-dependent manner. Thus, we exam-
ined whether the interaction between the de2-7 EGFR and Src
was a potential target of mAb 806 activity. If mAb 806 mediated
part of its antitumor activity by inhibiting this interaction, then
genetically disrupting this interaction using a DNSrc should have
reduced the efficacy of mAb 806. In contrast to this possibility,
the presence of a DNSrc dramatically enhanced the antitumor
activity of mAb 806. This suggests that Src has a role in limiting
the efficacy of EGFR therapeutics and provides a rationale for
using Src and EGFR inhibitors in combination.
Conclusion
These studies show the importance of in vivo studies for
analyzing the sensitivity of cell lines to EGFR therapeutics.
Unlike previous studies, we were able to conduct most of our
analysis in the same genetic background, making the predom-
inant variable the nature of the EGFR. Using this approach, we
conclusively showed the significance of receptor number to
efficacy. Although EGFR number is related to EGFR therapeutic
susceptibility, this factor alone is not enough as the receptor
also needs to contain a functional kinase. Indeed, although
somewhat intuitive, this work shows formally that ‘‘forcing’’ a
cell line to use EGFR signaling, either by overexpression of the
wt EGFR or expression of a constitutive active mutant, can
switch it from nonresponsive to responsive. Thus, the EGFR
must not only be present at the cell surface but must also be5 T.G. Johns et al., in preparation.
Fig. 11. Schematic representation of the
interaction of the de2-7 EGFR variants with
other cellular components.The de2-7 EGFR
has an active kinase and therefore can
autophosphorylate, transphosphorylate, or
be the target of phosphorylation by other
kinases. In contrast, the DK de2-7 EGFR can
only be the target of phosphorylation.
Finally, the DY5 construct can be the target
of phosphorylation and transphosphorylate
other cell targets, such as the wt EGFR.
Given that both mAbs 528 and 806 can
inhibit U87MG.DY5 xenografts but not
U87MG.DK xenografts, it suggests that
the ability of these antibodies to prevent
the phosphorylation of other cellular
components is critical to their antitumor
activity.
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significantly contributing the growth and survival of the cell.
Therefore, strategies for selecting patients who will respond to
EGFR therapeutics should be directed to identifying tumors
highly dependent on the EGFR, not only the presence or
absence of receptor protein. This task may be relatively
straightforward in some cases, such as when the de2-7 EGFR,
EGFR gene amplification, or kinase-activating mutants are
present, but is clearly more difficult in cases where the wt EGFR
is genetically normal. In these cases, the complex interplay of
multiple receptor kinases makes it difficult to identify those
tumors truly dependent on EGFR signaling. Long-term, detailed
expression profiling of yet to be identified target genes unique
to each receptor kinase may be the only viable approach to
addressing this problem.
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